Sotorasib successfully passed all testing phases, from in vitro KRAS c.34G > T (p.G12C) mutant cell lines to preclinical setting: its activity led to the inhibition of ERK phosphorylation and tumor cell growth, while the PI3K signaling was substantially unaffected [146,166]. This evidence concerns the gene PIK3CA and neoplasm.